Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Zealand sells rights to Takeda's blood cancer drug for $100M

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Zealand Pharma has sold its economic rights in Takeda and Protagonist Therapeutics' blood cancer drug rusfertide for $100 million ahead of an FDA approval decision, converting future royalties into immediate capital to fund its metabolic drug pipeline.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You have a clear example of turning potential royalty streams into upfront capital to accelerate drug development. If you're advancing clinical-stage assets, consider how royalty monetisation might fund your next product launch.

◆ Coverage

2 sources · 13 Aug 2026

◆ Related on Wire

◆ Topics

Biotechroyalty-saledrug-approvalbiotech-fundingFDAhematology